analyst meet takeaway goliath top
game buy rais pt
reiter buy rais pt
three-year organ revenu growth outlook rais first time
tmo recent histori underli market growth assumpt remain
rais organ revenu growth outlook typic
rang reflect compani expand exposur faster grow segment
within biopharma revenu emerg market revenu
believ tmo attract end market exposur happen overnight
speak compani strateg invest budget key
end market segment oper effici initi ppi last sever
year management also believ compani defens posit
recessionari environ past given significantli less exposur
industri market greater mix consum servic revenu furthermor
increasingli posit indispens partner
biopharma custom enabl product enhanc emerg
market china air qualiti monitor precis medicin
benefit disproportion also expect rel less
suscept pocket weak recent experienc peer
effect consolid capit deploy potenti billion
next three year assum gener adj net incom
year-end leverag project split vs
buybacks/dividend remain import part tmo longer-
term growth strategi strong track record achiev
oper effici target acquir asset also meaning improv
revenu growth profil life growth lsd msd/hsd fei
idc btig estim compani document
million except per share amount
lsd/msd msd/hsd patheon msd hsd
valuat revis revenu ep estim fulli reflect
tmo capit deploy potenti given uncertainti time pt
base price-to-earnings repres premium peer group averag
line multipl assum full capit deploy ratabl next three year
given tmo industry-lead ep growth potenti ahead could upsid
valuat faster capit deploy continu out-performance vs peer
valuat pt base price-to-earnings
largest compani life scienc tool industri better posit ever view
capit fastest grow market segment well take share competitor leverag
 budget economi scale strateg invest made last sever year high growth area
continu priorit oper effici initi better ever organ revenu growth
outlook capit deploy potenti ahead believ premium price-to-earnings multipl warrant
compar peer group larg cap life scienc tool compani
financi result midpoint compani guidanc
perform midpoint compani three-year
includ potenti futur acquisit gener in-lin
guidanc includ addit leverag full capit deploy
thermo fisher scientif
largest compani life scienc
tool industri revenu
reagent chemic suppli
servic research biopharma
industri diagnost clinic
appli market thermo also
provid scientif product
channel busi
thermo headquart
better-than-expect nt lt financi perform
faster-than-expect capit deploy
worse-than-expect nt lt financi perform
signific and/or prolong deterior demand across tmo end
model updat revenu ep estim y/i unchang y/i unchang
revenu ep estim bn y/i vs prior y/i vs
exhibit busi segment ltm vs ltm parenthes
note base revenu inter-compani elimin vs ltm revenu comparison
includ revenu anatom patholog busi expect divest
fiscal year end dec million except per share scienc diagnost product revenu profit profit develop expens incom non-oper non-oper expens incom tax incom incom analysiscost revenu margin gener administr develop margin tax margin growthlif scienc diagnost product bpssg incom bpsnet incom compani report btig estim
btig cover compani mention report
appendix analyst certif import disclosur
